# Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct04214262/  
OnCo record `nct04214262` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of atezolizumab and fludeoxyglucose F-18 (FDG) in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.

## Summary

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT04214262 by National Cancer Institute (NCI), with a registry enrolment figure of 415 participants, started 2020-08-13 and due to reach its primary completion in 2024-08-24. Interventions recorded: Atezolizumab; Biospecimen Collection; Computed Tomography; Fludeoxyglucose F-18; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy. Conditions listed: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8. Primary outcome: Overall survival. Lung eligibility wording from the registry: "* Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04214262
- Phase: 3
- Setting: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 415

## Sources

- ClinicalTrials.gov NCT04214262: https://clinicaltrials.gov/study/NCT04214262

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Fludeoxyglucose F-18 (FDG)](https://onco.cc/drugs/fludeoxyglucose-f18/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04214262.json